Assignee
IDEC PHARMA CORP
US·40 granted patents·17 pending applications·7,193 citations·filing 1992–2004
Top patents by PatentIndex Score
57 records- 0199US5736137ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1993·Granted Apr 7, 1998·1.6k cites·6 claims
- 0298US6455043B1Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodyIDEC PHARMA CORP·Filed 1999·Granted Sep 24, 2002·351 cites·15 claims
- 0398US6399061B1Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jun 4, 2002·254 cites·7 claims
- 0498US5776456ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jul 7, 1998·527 cites·14 claims
- 0598US5693780ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Dec 2, 1997·485 cites·16 claims
- 0698US5658570ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Aug 19, 1997·695 cites·38 claims
- 0797US6682734B1Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jan 27, 2004·176 cites·13 claims
- 0897US6136310ARecombinant anti-CD4 antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Oct 24, 2000·186 cites·16 claims
- 0997US6113898AHuman B7.1-specific primatized antibodies and transfectomas expressing said antibodiesIDEC PHARMA CORP·Filed 1995·Granted Sep 5, 2000·207 cites·11 claims
- 1097US5811524ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1995·Granted Sep 22, 1998·205 cites·11 claims
- 1197US5750105ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted May 12, 1998·318 cites·10 claims
- 1296US6846476B2Treatment of B-cell associated diseasesIDEC PHARMA CORP·Filed 2001·Granted Jan 25, 2005·100 cites·12 claims
- 1396US6001358AHumanized antibodies to human gp39, compositions containing thereofIDEC PHARMA CORP·Filed 1995·Granted Dec 14, 1999·125 cites·12 claims
- 1496US5958765ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Sep 28, 1999·185 cites·28 claims
- 1596US5756096ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted May 26, 1998·175 cites·6 claims
- 1696US5681722ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Oct 28, 1997·158 cites·8 claims
- 1794US6159730AImpaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameIDEC PHARMA CORP·Filed 1999·Granted Dec 12, 2000·123 cites·27 claims
- 1894US5866125ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Feb 2, 1999·86 cites·5 claims
- 1993US6413777B1Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the sameIDEC PHARMA CORP·Filed 1999·Granted Jul 2, 2002·120 cites·6 claims
- 2093US6413771B1Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1999·Granted Jul 2, 2002·60 cites·7 claims
- 2193US5939068ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Aug 17, 1999·83 cites·7 claims
- 2293US5840298ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Nov 24, 1998·75 cites·11 claims
- 2391US5955364ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Sep 21, 1999·63 cites·9 claims
- 2491US5830698AMethod for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the sameIDEC PHARMA CORP·Filed 1997·Granted Nov 3, 1998·76 cites·38 claims
- 2590US6011138AGamma-1 anti-human CD23 monoclonal antibodiesIDEC PHARMA CORP·Filed 1997·Granted Jan 4, 2000·93 cites·20 claims
- 2690US5733779AImpaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameIDEC PHARMA CORP·Filed 1995·Granted Mar 31, 1998·85 cites·30 claims
- 2790US5585103AInduction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1992·Granted Dec 17, 1996·97 cites·20 claims
- 2888US6841383B2Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the sameIDEC PHARMA CORP·Filed 2002·Granted Jan 11, 2005·17 cites·16 claims
- 2987US5695770AInduction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1995·Granted Dec 9, 1997·74 cites·9 claims
- 3086US5709860AInduction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1994·Granted Jan 20, 1998·73 cites·23 claims
- 3185US5648267AImpaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameIDEC PHARMA CORP·Filed 1993·Granted Jul 15, 1997·82 cites·10 claims
- 3284US6270769B1Induction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1995·Granted Aug 7, 2001·61 cites·35 claims
- 3384US5998144AMethod for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the sameIDEC PHARMA CORP·Filed 1998·Granted Dec 7, 1999·63 cites·45 claims
- 3480US6440418B1Methods of treating autoimmune diseases with gp39-specific antibodiesIDEC PHARMA CORP·Filed 1997·Granted Aug 27, 2002·36 cites·16 claims
- 3580US6207858B1Regioselective synthesis of DTPA derivativesIDEC PHARMA CORP·Filed 1999·Granted Mar 27, 2001·47 cites·29 claims
- 3673US6451284B1Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphyIDEC PHARMA CORP·Filed 2000·Granted Sep 17, 2002·11 cites·52 claims
- 3773US6017733AImpaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameIDEC PHARMA CORP·Filed 1998·Granted Jan 25, 2000·24 cites·10 claims
- 3860US2003021781A1Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 3959US2005112060A1Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combinationIDEC PHARMA CORP·Filed 2003·Application pending·0 cites
- 4058US6506383B1Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodiesIDEC PHARMA CORP·Filed 1999·Granted Jan 14, 2003·9 cites·27 claims
- 4158US2004258616A1Compositions and methods for treating cancer using IGSF9 and LIV-1IDEC PHARMA CORP·Filed 2004·Application pending·0 cites
- 4258US2004005323A1Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 2003·Application pending·0 cites
- 4357US2003206903A1Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibodyIDEC PHARMA CORP·Filed 2003·Application pending·0 cites
- 4457US2004213784A1Use of chimeric anti-CD20 antibody as in vitro or in vivo purging agent in patients receiving BMT or PBSC transplantIDEC PHARMA CORP·Filed 2004·Application pending·0 cites
- 4557US2003235533A1Prostate specific genes and the use thereof in design or therapeuticsIDEC PHARMA CORP·Filed 2003·Application pending·0 cites
- 4655US2003026804A1Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodyIDEC PHARMA CORP·Filed 2002·Application pending·0 cites
- 4753US2002128448A1Variant IgG3 Rituxan and therapeutic use thereofIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 4851US2002150580A1Recombinant antibodies for human therapyIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 4950US2003180290A1Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapiesIDEC PHARMA CORP·Filed 2002·Application pending·0 cites
- 5049US2003157641A1Polycistronic expression of antibodiesIDEC PHARMA CORP·Filed 2002·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →